• People
  • Locations

Nadia Tyler-Rubinstein

Patent Attorney

Nadia Tyler Rubinstein

Nadia is a Patent Attorney in the Biotechnology and Life Sciences Group. She joined the team in 2015.  Her work involves filing and prosecution of patent applications in the UK, Europe and worldwide.

Prior to entering the profession, Nadia received a PhD from the Clinical Sciences Centre of Imperial College London, uncovering the molecular mechanisms involved in insulin resistance and diabetes. Her work investigated the role of specific protein interactions within the insulin signalling network and their relevance to pathological states such as glucose intolerance, obesity, infertility and loss of spatial and working memory. She has specialist knowledge in a variety of topics including biochemical techniques, enzyme-based assays and in vivo transgenic animals.

Nadia also has a BSc (Hons) in Molecular Biology from the University of Manchester, and has worked at Thomas Jefferson University in Philadelphia on protein-based therapies to target and shrink tumours. Her work is published in the Journal of Biological Chemistry. Additionally, Nadia assists as an Editor for an online science and technology journal.

Memberships

CIPA

Qualifications

PhD Clinical Sciences, Imperial College London

BSc (Hons) Molecular Biology, University of Manchester

Sectors

Biopharmaceuticals

Metabolic diseases

Metabolic signalling

Molecular biology

Molecular Endocrinology

Pharmaceuticals

Practice areas

Antibodies

Cancer therapeutics

Cell culture

Enzymatic assays

Imaging techniques

Molecular and biochemical techniques

Transgenic animal models

Salisbury Square House
8 Salisbury Square
London
EC4Y 8AP
Download my vCard
 
View all insights

Contact us

The information you submit will exclusively be used to answer your enquiry. Find out exactly how we store and use your personal data in our privacy policy.

A European award-winning patent and trade mark firm delivering world-class advice to enhance the commercial value of intellectual property rights globally.